Multibagger pharma penny stock at Rs 10.59/share: Board is likely to announce 1:1 bonus share & 1:10 stock split
DSIJ Intelligence-1Categories: Bonus and Spilt Shares, Multibaggers, Penny Stocks, Trending
The stock is up by 65.5 per cent from its 52-week low of Rs 6.40 per share and has given multibagger returns of 600 per cent in 5 years.
On Monday, shares of Welcure Drugs & Pharmaceuticals Ltd hit a 5 per cent upper circuit to Rs 10.59 per share from its previous closing of Rs 10.09 per share. The shares of the company saw a spurt in volume by more than 1.40 times on the BSE.
A meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited is set for Friday, August 22, 2025. The board will consider two key proposals: a stock split of equity shares in a 1:10 ratio (one equity share into ten) and the issue of bonus shares up to a 1:1 ratio (one bonus share for every one held). These actions aim to boost the company's liquidity, expand its shareholding base and make shares more affordable for investors. Any approvals are subject to the board's decision and necessary regulatory and shareholder consents. Details regarding record dates and the timetable for these corporate actions will be announced later, in accordance with SEBI LODR and other applicable laws.
DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, download the service details here.
About the Company
Welcure Drugs & Pharmaceuticals Ltd, established in 1992, historically specialised in manufacturing and marketing a diverse range of pharmaceutical formulations, including tablets, capsules and dry syrups. Their extensive product portfolio covered various therapeutic categories like antibiotics, vitamins, analgesics and anti-diabetics, serving both Indian and international markets. With a recent strategic shift and improved financial performance, Welcure Drugs & Pharmaceuticals Ltd is now focused on achieving long-term sustainable growth.
The company reported a substantial financial upturn for the quarter ending June 30, 2025. Net profit soared to Rs 23.29 crore, an impressive 830 per cent increase quarter-on-quarter from Rs 2.5 crore in Q4FY25 and a significant recovery from a Rs 0.34 crore loss in Q1FY25. Revenue from operations dramatically rose to Rs 299.91 crore, nearly 1,300 per cent higher than Q4FY25's Rs 21.21 crore. The company has a market cap of Rs 119.15 crore. The stock is up by 65.5 per cent from its 52-week low of Rs 6.40 per share and has given multibagger returns of 600 per cent in 5 years.
Disclaimer: The article is for informational purposes only and not investment advice.